TSO3, a developer in sterilization technology for medical devices in healthcare settings, announced that the company has received purchase orders for multiple devices from the U.S. The orders are the result of the collaborative relationship between Getinge Infection Control, its sales and service provider, and TSO3.
“Finally,” said R.M. Rumble, president and CEO of TSO3. “Our Vision is to create the improved standard in healthcare sterile reprocessing; after spending years in development and working our way through the regulatory demands outlined when launching a new and novel technology, we have now received the first orders.”
About the STERIZONE VP4 low temperature sterilizer
The STERIZONE VP4 Sterilizer developed is a dual sterilant, low temperature sterilization system that utilizes vaporized hydrogen peroxide (H2O2) and ozone. Its single cycle can sterilize a large number and wide range of compatible devices, thereby allowing for a cost effective and error-free sterilization process. TSO3’s unique Dynamic Sterilant Delivery System automatically adjusts the quantity of injected sterilant based on the load composition, weight and temperature.
With its large 75 lb load capacity and a short cycle time, the STERIZONE VP4 Sterilizer can enhance throughput and lower sterilization cost. The STERIZONE VP4 Sterilizer was cleared for commercialization in the U.S. in December 2014.
“Every week the list of identified customer targets grows and our pipeline of quotations increases,” said Rumble. “We feel very good about the product’s initial launch and are working to implement even more ways to increase market awareness for our superior sterilizer. Needless to say, we are excited to add these new U.S. accounts to our base of Canadian customers.”